Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 24, 2026, 4:14 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 217–240 of 690 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Post-conditioning Clear all
Terminated Phase 2 Interventional Results available

CHOEP + High Dose Therapy + Auto SCT for T-Cell Lymphoma

NCT01746173
View directory record Official record
Conditions
T-cell Non-Hodgkin Lymphoma
Interventions
Cyclophosphamide, Doxorubicin, Vincristine, Etoposide, Prednisone, Filgrastim, Plerixafor, Stem Cell Collection, Palifermin, Gemcitabine, Busulfan, Melphalan, Stem Cell Transplant
Drug · Procedure
Lead sponsor
Dana-Farber Cancer Institute
Other
Eligibility
18 Years to 70 Years
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
2
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jan 30, 2023 · Synced Oct 24, 2026, 4:14 PM EDT
Recruiting No phase listed Observational Accepts healthy volunteers

Overlapping Pain Trajectory Study

NCT05752396
View directory record Official record
Conditions
Migraine, Musculoskeletal Pain, Functional Abdominal Pain Disorders, Chronic Pain, Widespread Chronic Pain, Low Back Pain, Healthy Volunteers
Interventions
Conditioned Pain Modulation, Offset Analgesia, Spatial Summation, Temporal Summation
Other
Lead sponsor
Children's Hospital Medical Center, Cincinnati
Other
Eligibility
10 Years to 19 Years
Enrollment
420 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2028
U.S. locations
1
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Oct 20, 2026 · Synced Oct 24, 2026, 4:14 PM EDT
Completed Phase 2 Interventional Results available

Targeting the IPA and Matching for the Non-Inherited Maternal Antigen for Haplo-Cord Transplantation

NCT01810588
View directory record Official record
Conditions
Hematologic Malignancies
Interventions
CliniMACS® CD34 Reagent System, Fludarabine, Melphalan, anti-thymocyte globulin (rabbit), Rituximab, Total Body Irradiation, Mycophenolate Mofetil, Tacrolimus
Device · Drug · Radiation
Lead sponsor
Weill Medical College of Cornell University
Other
Eligibility
18 Years and older
Enrollment
270 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2026
U.S. locations
2
States / cities
Chicago, Illinois • New York, New York
Source: ClinicalTrials.gov public record
Updated Aug 19, 2026 · Synced Oct 24, 2026, 4:14 PM EDT
Terminated Not applicable Interventional Accepts healthy volunteers

Effects of Aerobic and Resistance Training on Abdominal Fat Loss

NCT03700827
View directory record Official record
Conditions
Obesity, Abdominal
Interventions
Resistance Training, Aerobic Training
Other
Lead sponsor
Southern Illinois University Edwardsville
Other
Eligibility
18 Years to 35 Years · Female only
Enrollment
18 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2020
U.S. locations
1
States / cities
Edwardsville, Illinois
Source: ClinicalTrials.gov public record
Updated Oct 4, 2021 · Synced Oct 24, 2026, 4:14 PM EDT
Recruiting Phase 2 Interventional

Intensity Modulated Total Marrow Irradiation in Fully Human Leukocyte Antigen (HLA)-Matched and Partially-HLA Mismatched Allogeneic Transplantation Patients With High-Risk Acute Myeloid Leukemia (AML), Chronic Myeloid Leukemia (CML), and Myelodysplastic Syndrome (MDS)

NCT06802315
View directory record Official record
Conditions
Acute Myeloid Leukemia, Relapsed, Adult, Acute Myeloid Leukemia Refractory, Chronic Myeloid Leukemia - Accelerated Phase, Myelodysplastic Syndromes
Interventions
Intensity modulated total marrow irradiation, Cyclophosphamide (CTX), Fludarabine (Fludara), Busulfan (conditioning for ALLO Transplant)
Radiation · Drug
Lead sponsor
University of Illinois at Chicago
Other
Eligibility
18 Years to 65 Years
Enrollment
38 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2032
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Jun 26, 2026 · Synced Oct 24, 2026, 4:14 PM EDT
Recruiting Not applicable Interventional

LVAD Conditioning for Cardiac Recovery

NCT03238690
View directory record Official record
Conditions
Heart Failure
Interventions
Controlled Cardiac Reloading through LVAD Speed Adjustment
Device
Lead sponsor
STAVROS G DRAKOS
Other
Eligibility
18 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2028
U.S. locations
1
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Aug 13, 2026 · Synced Oct 24, 2026, 4:14 PM EDT
Terminated Phase 2 Interventional

Haploidentical Allogeneic Hematopoietic Stem Cell Transplantation (HaploHCT) Following Reduced Intensity Conditioning (RIC) for Selected High Risk Non-Malignant Diseases

NCT03367546
View directory record Official record
Conditions
Sickle Cell Disease, Thalassemia, High Risk Hematologic Disorders, Cerebral Adrenoleukodystrophy, Inherited Metabolic Disorders
Interventions
Blood and Marrow Transplant
Procedure
Lead sponsor
Masonic Cancer Center, University of Minnesota
Other
Eligibility
0 Years to 25 Years
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2022
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Jul 12, 2024 · Synced Oct 24, 2026, 4:14 PM EDT
Completed Phase 1Phase 2 Interventional

Strength Training and Stroke

NCT00629005
View directory record Official record
Conditions
Stroke
Interventions
Constraint-Induced Movement Therapy + strength training, Constraint-Induced Movement Therapy + range of motion
Behavioral
Lead sponsor
US Department of Veterans Affairs
Federal
Eligibility
18 Years to 85 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2011
U.S. locations
1
States / cities
Gainesville, Florida
Source: ClinicalTrials.gov public record
Updated Jan 29, 2013 · Synced Oct 24, 2026, 4:14 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Feasibility of a Train-the-Trainer Delivered Exercise Intervention in Firefighters

NCT05287594
View directory record Official record
Conditions
Firefighter, High Intensity Interval Training
Interventions
Integrated Exercise Program
Behavioral
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
18 Years to 60 Years
Enrollment
55 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2025
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Dec 19, 2025 · Synced Oct 24, 2026, 4:14 PM EDT
Completed Phase 2 Interventional Results available

Cyclophosphamide and Anti-thymocyte Globulin Followed By Methotrexate and Cyclosporine in Preventing Chronic Graft-Versus-Host Disease in Patients With Severe Aplastic Anemia Undergoing Donor Bone Marrow Transplant

NCT00343785
View directory record Official record
Conditions
Aplastic Anemia
Interventions
cyclophosphamide, anti-thymocyte globulin, cyclosporine, allogeneic bone marrow transplantation, methotrexate, DNA analysis, flow cytometry, polymorphism analysis, laboratory biomarker analysis
Drug · Biological · Procedure + 2 more
Lead sponsor
Fred Hutchinson Cancer Center
Other
Eligibility
Up to 65 Years
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2012
U.S. locations
3
States / cities
Salt Lake City, Utah • Seattle, Washington • Milwaukee, Wisconsin
Source: ClinicalTrials.gov public record
Updated Apr 13, 2017 · Synced Oct 24, 2026, 4:14 PM EDT
Active, not recruiting Not applicable Interventional

Personalized Mobility Interventions Using Smart Sensor Resources for Lower-Limb Prosthesis Users

NCT03930199
View directory record Official record
Conditions
Amputation
Interventions
Needs-based intervention (physical, psychological, or both)
Other
Lead sponsor
Shirley Ryan AbilityLab
Other
Eligibility
18 Years to 89 Years
Enrollment
66 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2026
U.S. locations
3
States / cities
Chicago, Illinois • Bethesda, Maryland • Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Jan 7, 2026 · Synced Oct 24, 2026, 4:14 PM EDT
Active, not recruiting Phase 3 Interventional

A Study of Bortezomib, Lenalidomide and Dexamethasone (VRd) Followed by Cilta-cel, a CAR-T Therapy Directed Against BCMA Versus VRd Followed by Lenalidomide and Dexamethasone (Rd) Therapy in Participants With Newly Diagnosed Multiple Myeloma for Whom ASCT is Not Planned as Initial Therapy

NCT04923893
View directory record Official record
Conditions
Multiple Myeloma
Interventions
Bortezomib, Dexamethasone, Lenalidomide, Cilta-cel, Cyclophosphamide, Fludarabine
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years and older
Enrollment
743 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2036
U.S. locations
19
States / cities
San Francisco, California • New Haven, Connecticut • Miami, Florida + 13 more
Source: ClinicalTrials.gov public record
Updated Sep 25, 2026 · Synced Oct 24, 2026, 4:14 PM EDT
Terminated Not applicable Interventional Results available

Stem Cell Transplantation for Children Affected With Osteopetrosis

NCT00145587
View directory record Official record
Conditions
Osteopetrosis
Interventions
Stem Cell Transplantation, Miltenyi Biotec CliniMACS, Systemic chemotherapy and antibodies
Procedure · Device · Drug
Lead sponsor
St. Jude Children's Research Hospital
Other
Eligibility
Not listed
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2009
U.S. locations
1
States / cities
Memphis, Tennessee
Source: ClinicalTrials.gov public record
Updated May 30, 2017 · Synced Oct 24, 2026, 4:14 PM EDT
Completed Not applicable Interventional

Thymoglobulin to Prevent Acute Graft vs. Host Disease (GvHD) in Patients With Acute Lymphocytic Leukemia (ALL) or Acute Myelogenous Leukemia (AML) Receiving a Stem Cell Transplant

NCT00088543
View directory record Official record
Conditions
Acute Myelogenous Leukemia (AML), Acute Lymphocytic Leukemia (ALL), Graft vs. Host Disease (GvHD)
Interventions
Thymoglobulin [Anti-Thymocyte Globulin (Rabbit)]
Biological
Lead sponsor
Genzyme, a Sanofi Company
Industry
Eligibility
18 Years to 55 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2006
U.S. locations
12
States / cities
Birmingham, Alabama • Los Angeles, California • Gainesville, Florida + 8 more
Source: ClinicalTrials.gov public record
Updated Mar 18, 2015 · Synced Oct 24, 2026, 4:14 PM EDT
Completed Phase 2 Interventional

Propranolol for the Treatment of Acute Stress Disorder

NCT00069355
View directory record Official record
Conditions
Stress Disorders, Traumatic, Acute
Interventions
Propranolol
Drug
Lead sponsor
National Institute of Mental Health (NIMH)
NIH
Eligibility
Not listed
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2004
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 4, 2008 · Synced Oct 24, 2026, 4:14 PM EDT
Recruiting Phase 1 Interventional

Anti-EGFRvIII synNotch Receptor Induced Anti-EphA2/IL-13Ralpha2 CAR (E-SYNC) T Cells

NCT06186401
View directory record Official record
Conditions
EGFR Gene Mutation, Glioblastoma, MGMT-Unmethylated Glioblastoma, Recurrent Glioblastoma
Interventions
E-SYNC T Cells, Cyclophosphamide (non-investigational), Fludarabine (non-investigational), Leukapheresis, Surgical resection
Biological · Drug · Procedure
Lead sponsor
Hideho Okada, MD, PhD
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Aug 13, 2026 · Synced Oct 24, 2026, 4:14 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

HLA-Identical Sibling Renal Transplant Tolerance

NCT00619528
View directory record Official record
Conditions
Immunosuppression, Kidney Transplantation, Graft Rejection
Interventions
Infusion of Donor Hematopoietic Stem Cells and Campath-1H
Biological
Lead sponsor
Northwestern University
Other
Eligibility
18 Years to 65 Years
Enrollment
88 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2023
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Feb 27, 2026 · Synced Oct 24, 2026, 4:14 PM EDT
Completed Not applicable Interventional

FRESH-TEEN: Families Responsibility Education Support Health for Teens

NCT03674944
View directory record Official record
Conditions
Overweight and Obesity
Interventions
Behavioral Weight Loss (BWL) + Emotion Regulation (ER), Behavioral Weight Loss (BWL)
Behavioral
Lead sponsor
University of California, San Diego
Other
Eligibility
13 Years to 16 Years
Enrollment
332 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2024
U.S. locations
2
States / cities
La Jolla, California • Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Sep 24, 2024 · Synced Oct 24, 2026, 4:14 PM EDT
Completed Phase 1Phase 2 Interventional

Intravenous Administration of RGI-2001 in Patient Undergoing Allogenic Hematopoietic Stem Cell Transplantation (AHSCT)

NCT01379209
View directory record Official record
Conditions
Graft Versus Host Disease
Interventions
RGI-2001, Calcineurin Inhibitors, Allogeneic Hematopoietic Stem Cell Transplantation, Conditioning Regimen, Allogeneic Bone Marrow Transplantation, Methotrexate, Mofetil Mycophenolate, sirolimus
Drug · Procedure
Lead sponsor
Regimmune Corporation
Industry
Eligibility
18 Years and older
Enrollment
68 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2017
U.S. locations
6
States / cities
San Diego, California • Stanford, California • Tampa, Florida + 3 more
Source: ClinicalTrials.gov public record
Updated Oct 23, 2019 · Synced Oct 24, 2026, 4:14 PM EDT
Completed Phase 1 Interventional

A Pharmacokinetic Study of Melphalan in Children

NCT02390544
View directory record Official record
Conditions
Hematopoietic Stem Cell Transplantation
Interventions
Melphalan
Drug
Lead sponsor
Children's Hospital Medical Center, Cincinnati
Other
Eligibility
Not listed
Enrollment
34 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
1
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Aug 30, 2021 · Synced Oct 24, 2026, 4:14 PM EDT
Completed Phase 1 Interventional Results available

Study of Donor Derived, Multi-virus-specific, Cytotoxic T-Lymphocytes for Relapsed/Refractory Neuroblastoma

NCT01460901
View directory record Official record
Conditions
Neuroblastoma
Interventions
GD2 CAR modified Tri-virus specific cytotoxic t-cells
Biological
Lead sponsor
Children's Mercy Hospital Kansas City
Other
Eligibility
18 Months to 17 Years
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2015
U.S. locations
1
States / cities
Kansas City, Missouri
Source: ClinicalTrials.gov public record
Updated Jul 23, 2019 · Synced Oct 24, 2026, 4:14 PM EDT
Completed No phase listed Observational Results available

EXErcise Regimen Designed to Improve Functional Mobility, Body Composition, and Strength After Treatment for Breast CA

NCT05747209
View directory record Official record
Conditions
Breast Cancer Female
Interventions
Observation of Exercise Program Adherence
Other
Lead sponsor
Colin Champ, MD
Other
Eligibility
20 Years to 89 Years · Female only
Enrollment
43 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jun 24, 2025 · Synced Oct 24, 2026, 4:14 PM EDT
Not listed Not applicable Interventional Accepts healthy volunteers

Operant Conditioning of Reflex Pathways to Improve Walking in Individuals Post-stroke

NCT05801744
View directory record Official record
Conditions
Stroke, Post-stroke Hemiparesis, Foot Drop
Interventions
Operant conditioning
Behavioral
Lead sponsor
University of Nevada, Las Vegas
Other
Eligibility
18 Years and older
Enrollment
5 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2025
U.S. locations
1
States / cities
Las Vegas, Nevada
Source: ClinicalTrials.gov public record
Updated Apr 6, 2023 · Synced Oct 24, 2026, 4:14 PM EDT
Recruiting Phase 2 Interventional

Blinatumomab After TCR Alpha Beta/CD19 Depleted HCT

NCT04746209
View directory record Official record
Conditions
B-cell Acute Lymphoblastic Leukemia, B-cell Childhood Acute Lymphoblastic Leukemia, B-Cell ALL, Childhood
Interventions
Alpha/Beta T-cell and B-cell depleted HCT, Blinatumomab
Device · Drug
Lead sponsor
Medical College of Wisconsin
Other
Eligibility
Up to 25 Years
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2029
U.S. locations
1
States / cities
Milwaukee, Wisconsin
Source: ClinicalTrials.gov public record
Updated Sep 17, 2021 · Synced Oct 24, 2026, 4:14 PM EDT